MOONLAKE IMMUNOTHERAPEUTICS Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-25
- MOONLAKE IMMUNOTHERAPEUTICS effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.10%.
- MOONLAKE IMMUNOTHERAPEUTICS effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.50%.
- MOONLAKE IMMUNOTHERAPEUTICS effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -12.30%.
- MOONLAKE IMMUNOTHERAPEUTICS effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -1.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 10 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|---|
| 2025-12-31 | -0.10% 10-K · filed 2026-02-25 | |
| 2024-12-31 | -0.50% 10-K · filed 2026-02-25 | |
| 2023-12-31 | -12.30% 10-K · filed 2026-02-25 | |
| 2022-12-31 | -1.40% 10-K · filed 2025-02-26 | |
| 2021-12-31 | -1.00% 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |